Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
04:15pm, Wednesday, 08'th Sep 2021
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th
89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH
08:30am, Monday, 02'nd Aug 2021
- Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints - - Study designed to build upon positive
89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 24'th Mar 2021
- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 -
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
11:00am, Saturday, 20'th Mar 2021
New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patient
89bio to Present at the Oppenheimer 31st Annual Healthcare Conference
08:00am, Thursday, 11'th Mar 2021
SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th
89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference
08:00am, Wednesday, 24'th Feb 2021
SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
89bio: NASH Drug Developer With Differentiated Profile
08:00am, Friday, 29'th Jan 2021
BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated.
89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
08:00am, Monday, 04'th Jan 2021
SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD's The Liver Meeting® 2020
08:00am, Friday, 13'th Nov 2020
– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing –
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update
04:02pm, Tuesday, 10'th Nov 2020
– Updated clinical data from BIO89-100 's Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting –
IPO Update: Metacrine Seeks $85 Million U.S. IPO
02:58pm, Friday, 11'th Sep 2020
Metacrine has filed to raise $85 million in an IPO of its common stock. The firm is developing treatments for NASH, a liver disease whose prevalence is increasing rapidly.
89bio (ETNB) Investor Presentation - Slideshow
02:00pm, Monday, 17'th Aug 2020
The following slide deck was published by 89bio, Inc. in conjunction with this event..
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update
08:05pm, Thursday, 13'th Aug 2020
\- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 - \- BIO89-100’s Phase 2 SHTG trial is expected to be initiated in Q3 -SAN FRANCISCO, Aug. 13, 2020
Why Earnings Season Could Be Great for 89bio (ETNB)
12:32pm, Tuesday, 11'th Aug 2020
89bio (ETNB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Much Of 89bio, Inc. (NASDAQ:ETNB) Do Institutions Own?
04:15pm, Monday, 10'th Aug 2020
Every investor in 89bio, Inc. (NASDAQ:ETNB) should be aware of the most powerful shareholder groups. Generally...
